Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 4CNS 3Myeloid 2Lymphoid 2Genitourinary 2Gastrointestinal 2NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Thymoma 1Sarcoma, Synovial 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Meningioma 1Medulloblastoma 1Glioma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Carcinoid Tumor 1Adrenal Gland Neoplasms 1Adrenal Cortex Neoplasms 1

Interventions

olaparib 1lutetium Lu 177 dotatate 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × olaparib × NET × Clear all
NCT06607692 2026-04-14

LUPARPED

Fundación de investigación HM

Phase 1/2 Recruiting
25 enrolled
CNSEndocrineNETSarcoma

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Paraganglioma, Pheochromocytoma, Recurrence, Osteosarcoma, Sarcoma, Synovial, Esthesioneuroblastoma, Olfactory, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡